Abstract: This review aims to describe analytic models of drug infusion that demonstrate the impact of the infusion system common-volume on drug delivery. The commonvolume of a drug infusion system is defined as the volume residing between the point where drug and inert carrier streams meet and the patient's blood. We describe 3 sets of models. The first is quantitative modeling which includes algebraic mathematical constructs and forwarddifference computational simulation. The second set of models is with in vitro benchtop simulation of clinical infusion system architecture. This modeling employs devices including pumps, manifolds, tubing and catheters used in patient care. The final set of models confirms in vitro findings with pharmacodynamic endpoints in living large mammals. Such modeling reveals subtle but important issues inherent in drug infusion therapy that can potentially lead to patient instability and morbidity. The common-volume is an often overlooked reservoir of drugs, especially when infusions flows are slowed or stopped. Even with medications and carriers flowing, some mass of drug always resides within this commonvolume. This reservoir of drug can be inadvertently delivered into patients. When infusions are initiated, or when dose rate or carrier flow is altered, there can be a significant lag between intended and actual drug delivery. In the case of vasoactive and inotropic drug infusions, these unappreciated time delays between intended and actual drug delivery can lead to iatrogenic hemodynamic instability. When a drug infusion is discontinued, drug delivery continues until the common-volume is fully cleared of residual drug by the carrier. The findings from all 3 sets of models described in this review indicate that minimizing the common-volume of drug infusion systems may enhance patient safety. The presented models may also be configured into teaching tools and possibly point to technological solutions that might mitigate sources of iatrogenic patient lability.
Introduction
Clinical care often requires continuous infusion of vasoactive, positive and negative inotropic, analgesic, anesthetic and sedative medications to critically ill patients in operating rooms, intensive care units, interventional radiology suites, and cardiac catheterization laboratories. Due to their profound rapid physiologic effects and high concentrations, combined with dynamic clinical circumstances of many of these patients, drug infusions can be surprisingly complex. Anecdotal evidence suggests that the complexity of drug infusions can lead to patient morbidity and mortality [1] .
Modern drug infusion systems have common basic elements: a reservoir, propulsion mechanism, flow controller, tubing, and an intravenous catheter ( Figure 1A ) [2] . Drug dissolved in solution starts in an infusions system's reservoir, either a bottle, plastic bag, or syringe. All intravenous drug infusion systems terminate in an intravenous catheter designed for insertion into a peripheral or central vein. Tubing systems connect the reservoir to the catheter. Every infusion system needs a method of propelling fluid. The simplest, least capital intensive, but perhaps least precise are gravity driven infusion systems. Sophisticated systems have electromechanical syringe or peristaltic infusion pumps which deliver fluid with considerably more precision; but sophisticated pumps can be very expensive and sometimes require custom disposables which may also be costly.
There are many reasons why drug infusion devices may not deliver drug as intended, including but not limited to startup delays within electromechanical systems [3, 4] , delayed occlusion alarms from slack mechanical components [5] [6] [7] , programming errors [8] , inaccuracies in electromechanical drive mechanisms especially at low flow [9, 10] , decreasing driving pressures within gravity driven systems as crystalloid bags empty [11] , and transient reflux of one drug into another syringe line when a catheter is obstructed [12] or one of multiple drugs are transiently stopped for syringe replacements [12, 13] .
Even if all elements of the infusion system including electro-mechanical pumps work perfectly as users expect, there is considerable nuance in how drugs come together inside infusion systems and interact with inert carrier flows in a common fluid pathway [1] . Unanticipated delays or transient perturbations in drug administration into the patient from these interactions can lead to iatrogenic morbidity. This review will focus on models that examine how drugs flow together in the common fluid pathway and thus assume that all of the electromechanical and disposable components are working in an ideal fashion.
The common-volume of a drug infusion system is defined as the volume between the point where drug and inert carrier streams meet and the patient's blood ( Figure 1B ). Downstream parts of infusion tubing, connectors, manifolds, and catheter lumens contribute to this volume. When flows are stopped, one can think of this volume as a "dead-volume": a reservoir for drug that will cause inadvertent immediate or delayed bolus effects. When drug flow first starts, one can also consider this deadvolume to be a void for drug to traverse. If multiple infusions are running, this volume can be considered to be a "common-volume" to all of the medications and inert carrier fluids. The terms common-volume and dead-volume are used essentially interchangeably in the published literature.
Common-volume is a seemingly easy concept to grasp; however, reports of adverse clinical incidents demonstrate that a lack of understanding continues to cause harm in daily practice. In a review of 4000 safety incidents reported to the Australian Incident Monitoring Study, 8 cases were attributed to tubing commonvolume; 6 of those 8 cases were due to succinylcholine remaining in the common-volume causing unintended muscle paralysis with administration of medication or fluid later in the perioperative period [14] . Additional reports described drug precipitation after inadvertent mixing of incompatible drugs (thiopental and vecuronium) in the common-volume, causing occlusion of the vascular access device [15] or precipitates producing signs of pulmonary emboli in animal models [16] . In an analysis of safety incidents involving neuromuscular blockade in the UK, one case details a patient who developed respiratory distress during the recovery period immediately after an IV tubing system was flushed, implicating bolus delivery of vecuronium accumulated in the common-volume [17] .
The above cited incidents are a result of potent, dangerous drug being left behind in infusion system common-volume. There are countless incidents that do not appear as case reports in the literature, but are instructive nonetheless. Several clinical vignettes that illustrate patient morbidity from the complexity of drug of infusion follow:
Clinical Vignette #1
A 58 year old male is schedule for a colectomy for adenocarcinoma. A combined general and low thoracic epidural anesthetic is planned. An epidural catheter is easily placed and general anesthesia is induced uneventfully. Bupivacaine 0.25 % is infused into the epidural catheter continuously at 8-10 ml/hr. A phenylephrine IV infusion propelled by an electromechanical pump is used intermittently to maintain the blood pressure. After emergenace from anesthesia, the patient arrived in the postanesthetic care unit with the infusion of phenylephrine flowing. The patient's vital signs on arrival are BP 151/70 mm Hg, HR 89 beats per minute, RR 14 per minute, O 2 saturation 99 %. The patient is somnolent but easily arousable and surgical pain appears to be well controlled. Moments later the blood pressure is 250/149 mm Hg and the pulse is 42 beats per minute.
Clinical Vignette #2
A 78 year old female with a ruptured cerebral aneurysm is obtunded and mechanically ventilated. Her blood pressure is controlled with a continuous nitroglycerin infusion flowing into a 9 French introducer sheath placed into her right internal jugular vein. She is transported to the interventional neuroradiology laboratory for angiography and possible embolization of a saccular intracerebral aneurysm. While being repositioned on the angiography table she becomes profoundly hypotensive.
Clinical Vignette #3
An 83 year old male is scheduled for coronary artery bypass grafting, aortic valve replacement and mitral valve repair. After induction of general anesthesia, a pulmonary arterial catheter is inserted through a sheath in the right internal jugular vein. The patient is placed on cardiopulmonary bypass (CPB). Upon separation from prolonged CPB, the patient is hypotensive with a low cardiac index necessitating pharmacologic support with infusions of norepinephrine (NE), milrinone, epinephrine and vasopressin. The patient arrived in the intensive care unit (ICU) in "stable condition" with the following drug infusions: NE 20 mcg/min, epinephrine 3 mcg/min, milrinone 0.5 mcg/kg/min and vasopressin 0.06 units/min. Ten minutes after arrival the blood pressure plummets. The NE infusion is increased in rapid increments to 60 mcg/min without significant effect. A few minutes later the systolic blood pressure soars to over 200 mm Hg.
Clinical Vignette #4
An elderly man undergoes a urology procedure under general anesthesia. One intravenous line is used to deliver antibiotics, analgesics, antiemetics and other routine drugs. A second intravenous line is used to deliver cisatracurium by infusion, which enters the main fluid pathway via a manifold. At the conclusion of surgery, drug and carrier flow through the second intravenous line is stopped and that line is separated into two parts just upstream of the manifold. The first intravenous line is used to administer neuromuscular blockade reversal agents. The patient emerges from general anesthesia without incident and is brought to the recovery unit in good condition. In the recovery unit, the nurse connects the second IV to an infusion set. Moments later the patient stops breathing.
Clinical Vignettes Explained
These vignettes illustrate the complexity of drug infusion which gives rise to morbidity resulting from the patient's caregivers not fully appreciating the nuance of drug infusion. In Vignette #1, the team transferring the patient to the PACU placed the crystalloid carrier bag ( Figure 1A ) on a low pole for transport while the phenylephrine was still flowing. When the patient arrived in the PACU the bag was placed on an elevated hook and immediately delivered the phenylephrine that had accumulated in the infusion tubing as a bolus. In the second vignette, concentrated nitroglycerin was flowing into a 9 French introducer sheath and thus the common-volume shown in Figure 1A is over 3.2 mL [18] . As much as one mg of nitroglycerin was inadvertently administered to this patient when an inert carrier flow was either initiated or the rate increased by elevating the carrier bag. In Vignette #3, the carrier used in transport by the anesthesia team was gravity driven (as shown in Figure  1A ) and likely to be between 100 and 200 ml/hr. On arrival in the ICU, the nurses by protocol immediately changed the carrier flow to 10 ml/hr driven by a peristaltic pump. The delivery rate of vasoconstrictive and inotropic medications was immediately lowered by this loss of carrier flow while the medications accumulated at higher concentrations inside the drug infusion common-volume. The resulting drop in blood pressure prompted the ICU team to increase the dose rate of NE several times. When the concentrated drugs finally emerged from the catheter and into the blood stream, the blood pressure soared. In Vignette #4, the commonvolume of the infusion system stored a mass of cisatracurium when flow was stopped and the infusion system was divided into proximal and distal portions. Resuming flow through the common-volume delivered a bolus of cisatracurium to the patient. These four vignettes are all real cases that demonstrate a lack of appreciation for the dangers inherent to drug infusion system common-volume.
Common-volume analysis
Infusion system architectures with multiple infusions and an inert carrier converging on a manifold connected to an intravenous catheter give rise to many considerations for safe use. Initial analysis can be accomplished with quantitative modeling. When all of the flows stop, the common-volume may function as a reservoir for a mass of forgotten drug. Even if medications and inert carriers are flowing, some mass of drug always resides within the common-volume (V) that can be estimated from the concentration in the reservoir (C res ), the drug (Q d ) and carrier (Q c ) flow rates [19] :
This drug mass can be accidentally delivered into patients if medications (e. g. antibiotics, muscle relaxants, opiates, anesthetics) are pushed upstream, carrier flows are suddenly increased, or another drug infusion is started at a high flow rate [19] [20] [21] [22] . Indeed, this quantitative analysis could help predict the impact of provider inattention to the carrier flow rate as was illustrated in several of the clinical vignette's. In Vignette #1 the carrier was essentially stopped and eq. (1) predicts that the mass of phenylephrine in the infusion system was up to the concentration of drug in the reservoir multiplied by the common-volume. If V was 1.5 ml and the concentration of phenylephrine in the bag, was 200 mcg/ml, the delivered bolus of phenylephrine would be up to 300 mcg upon restarting the carrier. Similarly, in vignette #2, c res for nitroglycerin was 400 mcg/ml which flowed into a 9 Fr access sheath (V > 3.2 mL) leading to a potential bolus of over 1.2 mg of nitroglycerin. Benchtop (in vitro) modeling of initiating a drug infusion or changing the dose rate of an ongoing infusion shows that there can be a significant lag for the new concentration at the upstream side of the commonvolume to propagate to the patient and achieve the intended steady state delivery. This lag time can lead to delays in intended dose delivery that, under some conditions, can be surprisingly long [12, 18, 20, 21, 23] . For infusions into standard central venous catheters of sizeable dead-volume (9 Fr introducer sheath, dead volume~3.2 ml) with inert carrier flow rates designed to minimize excessive fluid administration (10 ml/hr), steady-state drug delivery rates may not be fully realized for over 20 min [18] . Much iatrogenic morbidity and patient lability can be traced back to lack of appreciation for these potentially significant delays [1, 18] .
The magnitude of these transient pharmacologic delay phenomena is proportional to the common-volume of the infusion system and inversely proportional to the total flow rate through it. Use of significantly higher carrier flow rates could minimize these issues at the expense of administering more fluid. For OR management, more liberal fluid administration may not have deleterious effects. However, the fluid volume administered associated with high carrier flows may be a source of morbidity for many ICU patients [24] [25] [26] .
Models of drug infusion
The clinical vignettes suggest that clinicians may believe that drug infusion is a straightforward process. However, in reality there is much complexity in the nuances of drug infusion. Problems in drug dosing can come from startup delays of syringe pumps [3, 4] , errors in device calibration [9, 10] , and the complex interaction between multiple infusion devices with different compliances and flow rates through syringes of different barrel sizes leading to potential transient backflow [12, 13] . Each of these can result in drug administration that deviates from the user's intent. Even if these sources of error could be completely eliminated through technical innovation, lags between drug delivery and user intent arise from the commonvolume.
How should clinicians be guided to easily recognize the pitfalls of drug infusion and avoid iatrogenic morbidity from the infusion system common-volume? We have devised a series of models that may help set clinical guidelines, allow the creation of educational tools, and suggest future technologies to mitigate risk. Quantitative models vary in sophistication from simple algebraic mathematical constructs, to software based forward-difference computational simulations. Physical models include in vitro bench top demonstrations with in vivo verification in large mammals using drugs with measurable pharmacologic effects. Finally, living animal simulators have been used to demonstrate the extent to which mechanical solutions can influence human performance.
Algebraic mathematical constructs
The simplest quantitative model of drug infusion assumes that all drug moving in the common-volume moves at the same rate, that there is no dispersion (Figure 2A ) [20] . In this "plug flow" construct, every change in drug or carrier flow creates an abrupt step change in drug concentration that propagates uniformly down the tubing of the common-volume. Under such idealized conditions, the time from drug flow onset to full steady-state drug delivery is one time constant, τ [20] :
In reality, drug infusion should take longer to reach steady-state as there is dispersion of the moving front of concentrated drug. One could assume maximal drug dispersion in the infusion tubing. In this "well mixed" model, all of the common-volume is considered one homogenous compartment ( Figure 2B ) [20] . If drug infusion is initiated with a steady carrier, and the commonvolume initially contains no drug, this model predicts the concentration inside the volume to be:
Drug delivery at any instant in time (t) is this concentration multiplied by the total flow rate. The concentration after any change in carrier or drug flow from steady-state can be described by [20] : where Q c ' and Q d ' are the carrier and drug flow rates after making any changes, respectively. Changes in drug infusion or carrier rate slowly change the concentration in this well mixed compartment to a new concentration over 3 time constants, and thus take this long to reach steady state drug delivery.
In vitro models of drug infusion
In vitro models, using dyes such as methylene blue as a quantifiable drug tracer and the collection of timed samples exiting the terminus of an infusion system, show that drug delivery out the end of the common-volume shows features of both the plug flow and well mixed models [20] . When drug delivery is initiated there is a delay for drug to initially traverse the common-volume which is well predicted by the plug flow model ( Figure  2C ). The slow transition from zero to steady state drug delivery is described by the well mixed model. Actual drug delivery can be considered to be bound between the extremes of these two models. Thus, in vitro models validate the bounds set by the plug-flow and well-mixed models.
Together these algebraic mathematical constructs and the in vitro models can help guide clinical care. Flow rates of drugs and carriers are easily estimated from the settings on electromechanical infusion pumps or from drop rates using infusion tubing with calibrated drop sizes [1, 27] . Catheter priming volumes are usually labeled on packaging or can be measured. Drug infusion ports such as stopcocks each add to the common volume and their internal volume is typically around 0.3 ml. Thus, the common-volume can be estimated and the time constants calculated (eq. 2). As demonstrated by both algebraic mathematical constructs and in vitro modeling, in many clinical circumstances one should wait for at least the duration of two -three time constants before making other adjustments to flow rates.
These simple guidelines might have prevented the iatrogenic hemodynamic lability described in Vignette #3. The ICU nurses decreased the carrier flow rate from 200 to 10 ml/hr and the delivery of norepineprhrine instantaneously decreased. Moments later the blood pressure fell. The total flow rate through the catheter might have been about 30 ml/hr considering the rates of all of the infused drugs. If they were administered to the side port of a 9 Fr introducer sheath (V over 3.2 ml) the time constant after the carrier was lowered would be over 6 min. The delivery of norepinephrine would take 12-18 min or more (at least two to three times constants) to be restored to equilibrium. Thus, in this third Vignette prematurely raising the dose of norepinephrine leads to iatrogenic hypertension. Patience on the part of the care team, or lowering the carrier rate in small increments from 200 to 10 ml/hr over 30 min, would have resulted in much smoother management of blood pressure.
Computational simulations
Simple mathematical constructs allow quick calculation of propagation delays for drug to traverse the commonvolume and provide a useful clinical guide. However, there is much utility in refined models of drug infusion. Forward-difference computational methodology can be used to precisely predict drug movement inside the common-volume of infusion systems [28, 29] . In these techniques, the common-volume is modeled as a series of small discrete nodes each having a single drug concentration (c). The flux of drug across the interface of each node is calculated from both convective and diffusive forces ( Figure 3A) . Taylor diffusion recognizes that the dispersion is related not only to the diffusivity of the drug in aqueous solutions (D), but also to the average fluid velocity ( u) and radius of the tube (R). The one-dimensional equation of drug motion is [28] :
where x is space and t is time. At each location and at each time step, the diffusive and convective flux is calculated such that:
This equation assumes that the common-volume has a single radius and requires an estimate of the diffusivity in aqueous solutions (which is not readily available for many compounds). Furthermore, it ignores the impact of turns in the fluid path and gravitational effects. An example of computational forward-difference simulations of drug delivery is compared to in vitro data ( Figure 3) . These computational models can be used to predict the consequence of an action, such as changing drug dose or inert carrier flow rate. They can also be used to calculate the time to steady state drug delivery, and thus could be configured to be a real-time guide to clinicians. If they are constructed to track two drug species separately, the models could illustrate how changes to one medication's dose (flow rate) may transiently impact the delivery of another. Computational simulations can also be incorporated into offline teaching tools that may allow users to internalize the potential risks of medication infusion and manners in which they practice. Finally, they can be used to help develop novel technologies for mitigating the risks associated with the common-volume of drug infusion. Algorithms for coordination and control of both the drug and carrier pump have allowed significantly faster achievement of steady state drug delivery in vitro, and biologic effect in vivo than conventional drug administration through infusion systems with clinically relevant common-volumes [28, 29] .
In vivo models
Before clinical implementation, the physiologic relevance of the findings from quantitative mathematical and in vitro modeling need to be evaluated. In vitro data have been confirmed in vivo using large animal models, which allow measurement of pharmacodynamic endpoints. The simplest of these in vivo models utilizes infusions of catecholamines such as epinephrine or norepinephrine which have easily measured endpoints of blood pressure or indices of myocardial contractility (max dP/dt) [30] . In a series of in vivo experiments using healthy anesthetized adolescent swine, epinephrine was infused at 0.1 mcg/kg/ min (3 mL/hr) for 30 min and then turned off. This infusion was connected to an inert carrier infusion (10 mL/hr) through either a high or low common-volume infusion system. The large common-volume system was composed of a bank of 4 connected stopcocks ( Figure 4A ) fed into a 16 gauge × 15 cm single lumen catheter (commonvolume about 1.27 mL). A novel drug infusion manifold (Edelveiss Multiline, Doran International, Toussieu, France) wherein all the medications flow coaxially down a multi-channeled tube and only meet at the distal tip, thus eliminating the manifold contribution to infusion system common-volume ( Figure 4B ), was connected to the single lumen catheter (low V = 0.22 mL). In vitro data show that drug emerges from the infusion system and reaches steady state much faster with the low compared to the high common volume system ( Figure 5A ) [30] . When the drug infusion is turned off, drug delivery ends within minutes with the low commonvolume infusion system, whereas with the high volume system, drug may still be delivered for over 20 min.
In vivo data demonstrate that these delays in drug delivery are not just theoretical [30] . Biologic response was significantly delayed by using a high common- (A) The common-volume is modeled as a series of small discrete nodes, each with finite volume and homogenous concentrations. At each time increment, the diffusive/dispersive transport of drug across both faces of the node is calculated as well as the convective bulk transport. The forward-difference technique calculates the difference in concentration between the nodes to calculate the diffusive transport assuming Taylor dispersion (Eq. 6) [28] . (B) Forward-difference simulations predict in vitro drug initiation (Q d = 3 ml/ hr, c d = 0.1 mg/ml, V = 0.54 mL, Q c = 10 ml/hr). N = 6, AVG ± SD.
volume infusion system ( Figure 5B) . Similarly, when drug was discontinued the pharmacodynamic effect persisted for significantly longer with the high common-volume system. These in vivo data demonstrate the lag time between making a change at the pump and drug delivery response is as long as, if not longer than the time for drug to circulate and act in the animal model. Thus, in vivo models show that the delays inherent in infusion systems can have a significant pharmacodynamic impact.
Similar in vivo models have demonstrated that changes to carrier flow rate can impact both the drug delivery and the biologic response. In another series of experiments, during steady state NE infusion, the inert carrier was transiently turned off for 10 min [22] . Drug delivery and biologic effect (mean arterial pressure, MAP) decreased rapidly ( Figure 6A ). With the small common volume infusion system, drug delivery and biologic effect returned to steady state within minutes. With the large common-volume these stayed low for the entire time the carrier was off. On resumption of the carrier, concentrated drug which accumulated in the common-volume was rapidly delivered resulting in a bolus of NE and an increase in blood pressure. These effects were magnified for the drug infusion system with the larger common volume. This pehenomenon may help explain the morbidity suffered by the patient in Vignette's #1 and #2, who each received a bolus of potent vasoactive medication upon resumption of a stalled carrier flow.
If a drug is flowing steadily and a second drug infusion is started using the same infusion line, this second drug adds to the carrier for the primary drug ( Figure 6B ). In vitro and in vivo models demonstrate that both drug delivery and biologic response to the primary drug transiently rise but then return to steady state. Upon cessation of the secondary infusion, the opposite occurs. The primary drug's delivery and biologic response fall. These perturbations in drug delivery and biologic response are magnified in infusion systems with higher commonvolume. Thus, in vivo models demonstrate that under many clinically relevant conditions the propagation delays inside the common-volume can lead to undesired pharmacologic effects, hemodynamic lability, and potential morbidity. This has been demonstrated numerous times with infusions of catecholamines. Drugs in this class have short half-lives in plasma, and therefore reach steady state quickly when infused [31] . In contrast, for drugs with long half-lives delays in delivery from traversing the common-volume may be insignificant compared to the time needed to reach steady state plasma concentration [1] . Examples of drugs with long half-lives in the blood include milrinone, vasopressin, some analgesic agents, diuretics and anticoagulants. For such drugs, the impact of common-volume on delaying therapeutic goals is likely to be less significant than for drugs with short half-lives. This remains to be tested.
Human performance assessment of hemodynamic management using a living simulation model
One can question whether the delay between clinician intent and achieving steady state drug delivery is of clinical significance in patient management. It is possible that some clinicians, through vigilance, experience and skill can overcome the disadvantages that arise from the effects of the common-volume. A living swine simulator of hemodynamic instability was used to determine if the magnitude of the infusion system common-volume impacted the ability of experienced intensive care unit (ICU) nurses to maintain blood pressure within a specific range [32] . Occlusion balloons were placed in the thoracic aorta and inferior vena cava (IVC) to rapidly raise or lower blood pressure. Experienced ICU nurses were tasked to maintain blood pressure using only infusions of norepinephrine or sodium nitroprusside. The nurses were blinded to the timing and type of balloon occlusion but had full access to hemodynamic monitors. Representative mean arterial pressure (MAP) data after aortic occlusion and release ( Figure 7A ) or IVC occlusion and release ( Figure 7B ) suggest that blood pressure is restored to target range faster, and total time spent out of target range is less, for infusion systems with smaller common volume. The aggregate data showed that hemodynamic stability was more easily restored after balloon occlusion perturbation when the medications were infused via a smaller common-volume infusion system ( Figure 8 ). Thus, one might infer that infusion system architecture plays a role in achieving therapeutic goals in a living simulator of hemodynamic stability, even in very experienced hands. 
Conclusion and future perspectives
All infusion systems have the potential for iatrogenic morbidity from unappreciated residual drug in the common-volume and unappreciated delays in the kinetics of drug administration by infusion. We describe 3 sets of models including quantitative, in vitro and live animal, which allow evaluation of the role of the common-volume in drug delivery. The predictions of computational analyses are comparable to findings from in vitro (benchtop) experimental models which simulate routine clinical practice. Large mammalian models confirm the impact of the common-volume on biologic response in living beings. Finally, living simulator models have demonstrated that even with experienced clinicians, infusion system architecture impacts expeditious pharmacologic restoration of hemodynamic stability. Each model suggests that minimizing the commonvolume within infusion systems will reduce the risk from unintended bolus administration of a potent drug. If the common-volume had been minimized, the bolus of phenylephrine in Vignette #1 and nitroglycerin in Vignette #2 would have been smaller and the patients would likely have suffered less hemodynamic instability. Similarly, in Vignette #4 the risk of life-threatening respiratory compromise might have been mitigated. Furthermore, an infusion system with a low common-volume will have a better response time to changes of settings at the drug pump potentially resulting in less hemodynamic lability and iatrogenic morbidity and might have benefitted the A living swine simulator was used to determine if the magnitude of the infusion system common-volume impacted the ability of experienced intensive care unit (ICU) nurses to maintain blood pressure within a specific range in a model of hemodynamic instability. Occlusion balloons were placed in the thoracic aorta and inferior vena cava (IVC) to rapidly raise or lower blood pressure. ICU nurses were tasked to maintain the blood pressure using only infusions of norepinephrine or sodium nitroprusside. The nurses were blinded to the type and timing of balloon occlusions but had full access to hemodynamic monitors. Representative samples of MAP data during and after aortic and IVC occlusion are shown. Hemodynamic stability was more easily restored after balloon occlusion perturbation with a smaller common-volume (0.22 ml) infusion system than with a large one (3.4-3.7 ml). (Reprinted from reference 32 with permission).
patient in Vignette #3. Overall, models will provide the backbone for initiatives to educate clinicians about the complexity of drug infusion that will ultimately improve patient safety. They also bolster the imperative to adopt common-volume reducing or other technologies to mitigate some of the pitfalls inherent within modern drug infusion systems.
